Psoriasis is a chronic, immune-mediated disorder characterized by well demarcated, erythematous plaques covered by thick, silvery-white scales, most often located on the knees, elbows, sacral area and scalp. It has a significant impact on the patient's quality of life.
Introduction
Psoriasis is a chronic, immune-mediated disorder characterized by well demarcated, erythematous plaques covered by thick, silvery-white scales, most often located on the knees, elbows, sacral area and scalp. Any region however can be involved. It has a worldwide distribution and a prevalence of approximately 2%. It can occur at any age but it presents two peaks of onset:
one at 20-30 years and the second at 50-60 years.
Psoriasis has a significant impact on the patient's quality 
Infections
Tuberculosis is one of the most important adverse events associated with biological therapies. Those can determine the reactivation of a latent tuberculosis or de novo infection. The risk of extrapulmonary tuberculosis is also higher in these patients. Given the high incidence of this infection in the general population, testing all patients prior to starting biological treatment is mandatory (8) .
A study performed in Sweden by Asklinget al. 
Development of anti-drug antibodies
Biological therapies act as antigens after they are administered because of their protein structure. As a result, the immune system can create antibodies directed against them. The development of anti-drug antibodies was reported for all biological therapies. Two main types of anti-drug antibodies were described in the medical literature: neutralizing antibodies, which decrease or even annul the effect of the biological agent, and nonneutralizing antibodies, which do not influence the pharmacological proprieties of the drug (2, 23).
Infliximab is a chimeric mouse-human monoclonal antibody and its administration is frequently associated with the development of anti-drug antibodies which are generally neutralizing. Adalimumab is a fully human monoclonal antibody. For that reason, it was initially believed that it would not be recognized as non-self by the immune system. Recent studies however contradict this idea, as neutralizing antibodies directed against adalimumab were detected. Etanercept is a fusion protein produced by recombinant DNA technology.
Anti-drug antibodies were described in patients treated with etanercept but these antibodies are not neutralizing Data regarding their usefulness in patients with psoriasis is contradictory and additional studies are needed to support the efficiency of the combined treatment (27) .
Neurological adverse events
The most important neurological side-effects A study which included 173 psoriasis patients who were prospectively followed for 5 years also showed that long-term treatment with biologicals is safe in this group of patients, the rate of malignancies, serious infections and serious cardiovascular events being comparable with the general population incidence rate. The authors also found that psoriatic patients treated with anti-TNF-α agents have a higher risk of developing skin malignancies, probably due to previous exposure to UVtherapies and immunosuppressive drugs, but also because these patients are more closely followed by dermatologists (41) .
Conclusions
Psoriasis vulgaris is a chronic, inflammatory disease 
